Sareum Announces Cancer Collaboration with Roche
Complete the form below to unlock access to ALL audio articles.
Sareum Holdings plc has announced that it has entered into a collaborative agreement with Roche to provide protein structure determination capabilities to accelerate Roche’s cancer drug discovery research.
Sareum will use its skills in protein engineering and high throughput protein structure determination to illustrate the nature of how Roche’s potential drug candidates interact with target receptor proteins.
This detailed structural information will support Roche’s scientists in their search for improved cancer therapeutics by assisting lead optimisation results and providing co-complex structures for Roche’s compounds.
Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, "We are delighted that Roche has chosen Sareum as their partner in protein structure determination."
"This is a further important collaboration that Sareum has signed with a major global pharmaceutical company and further validation that Sareum is a partner of choice for structure-based drug discovery."
